These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 28229812)
1. Successful extension of tocilizumab infusion intervals from 4 weeks to 6 or 5 weeks in 90% of RA patients with good response to 4-week intervals. Saiki O; Uda H Clin Exp Rheumatol; 2017; 35(4):666-670. PubMed ID: 28229812 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of extending intravenous tocilizumab intervals from 4 to 6 weeks in rheumatoid arthritis patients with good response to 4-week intervals. Saiki O; Uda H Rheumatol Int; 2018 Dec; 38(12):2307-2313. PubMed ID: 30206670 [TBL] [Abstract][Full Text] [Related]
3. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Bao M; Rowell L; Davies C; Mysler EF Ann Rheum Dis; 2016 Jan; 75(1):68-74. PubMed ID: 26056119 [TBL] [Abstract][Full Text] [Related]
5. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52. Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408 [TBL] [Abstract][Full Text] [Related]
6. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis]. Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335 [TBL] [Abstract][Full Text] [Related]
7. Utility of Dose Frequency Adjustment in Tocilizumab Administration for Rheumatoid Arthritis. Saito S; Kaneko Y; Izumi K; Takeuchi T J Rheumatol; 2017 May; 44(5):553-557. PubMed ID: 28298563 [TBL] [Abstract][Full Text] [Related]
8. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study. Weinblatt ME; Kremer J; Cush J; Rigby W; Teng LL; Devenport J; Singh N; Lepley D; Genovese MC Arthritis Care Res (Hoboken); 2013 Mar; 65(3):362-71. PubMed ID: 22972745 [TBL] [Abstract][Full Text] [Related]
9. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Garnero P; Thompson E; Woodworth T; Smolen JS Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI. Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733 [TBL] [Abstract][Full Text] [Related]
11. A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis. Saito S; Suzuki K; Yoshimoto K; Kaneko Y; Matsumoto Y; Yamaoka K; Takeuchi T Arthritis Res Ther; 2017 Oct; 19(1):231. PubMed ID: 29041951 [TBL] [Abstract][Full Text] [Related]
12. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. McLaughlin M; Östör A Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607 [TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Nakashima Y; Kondo M; Harada H; Horiuchi T; Ishinishi T; Jojima H; Kuroda K; Miyahara H; Nagamine R; Nakashima H; Otsuka T; Saikawa I; Shono E; Suematsu E; Tsuru T; Wada K; Iwamoto Y Mod Rheumatol; 2010 Aug; 20(4):343-52. PubMed ID: 20480201 [TBL] [Abstract][Full Text] [Related]
14. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. Nishimoto N; Amano K; Hirabayashi Y; Horiuchi T; Ishii T; Iwahashi M; Iwamoto M; Kohsaka H; Kondo M; Matsubara T; Mimura T; Miyahara H; Ohta S; Saeki Y; Saito K; Sano H; Takasugi K; Takeuchi T; Tohma S; Tsuru T; Ueki Y; Yamana J; Hashimoto J; Matsutani T; Murakami M; Takagi N Mod Rheumatol; 2014 Jan; 24(1):26-32. PubMed ID: 24261755 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis. Iwamoto N; Fukui S; Umeda M; Nishino A; Nakashima Y; Suzuki T; Horai Y; Nonaka F; Okada A; Koga T; Kawashiri SY; Fujikawa K; Aramaki T; Ichinose K; Hirai Y; Tamai M; Nakamura H; Terada K; Nakashima M; Mizokami A; Origuchi T; Eguchi K; Ueki Y; Kawakami A Mod Rheumatol; 2016 Sep; 26(5):662-6. PubMed ID: 26708444 [TBL] [Abstract][Full Text] [Related]
16. Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review. Hayakawa M; Izumi K; Higashida-Konishi M; Ushikubo M; Tsukamoto M; Akiya K; Araki K; Oshima H Rheumatol Int; 2019 Jan; 39(1):161-166. PubMed ID: 30357484 [TBL] [Abstract][Full Text] [Related]
17. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Strang AC; Bisoendial RJ; Kootte RS; Schulte DM; Dallinga-Thie GM; Levels JH; Kok M; Vos K; Tas SW; Tietge UJ; Müller N; Laudes M; Gerlag DM; Stroes ES; Tak PP Atherosclerosis; 2013 Jul; 229(1):174-81. PubMed ID: 23746537 [TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study. Sagawa A Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804 [TBL] [Abstract][Full Text] [Related]
19. Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study. Gossec L; Steinberg G; Rouanet S; Combe B Clin Exp Rheumatol; 2015; 33(5):664-70. PubMed ID: 26344671 [TBL] [Abstract][Full Text] [Related]
20. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study. Ogata A; Amano K; Dobashi H; Inoo M; Ishii T; Kasama T; Kawai S; Kawakami A; Koike T; Miyahara H; Miyamoto T; Munakata Y; Murasawa A; Nishimoto N; Ogawa N; Ojima T; Sano H; Shi K; Shono E; Suematsu E; Takahashi H; Tanaka Y; Tsukamoto H; Nomura A; J Rheumatol; 2015 May; 42(5):799-809. PubMed ID: 25834203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]